ArticleBlood advances2023

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

Stéphane de Botton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.